MSDS's can now be found on the Homepage under Physicians and Pharmacists.

Fougera does not participate in any Indigent programs at this time.

Our Sales force does not visit doctor’s offices. If you have any questions regarding the Fougera line of products please e-mail us at info@fougera.com or call our Customer Service Department at 1-800-645-9833.

For all inquiries regarding Fougera packaging, damages, ingredients, etc., please contact Customer Service in the contact us section of the website or call us at 1-800-645-9833. FOR CROFAB® OR DIGIFAB® ONLY: If this is a medical emergency or a medical question relating to either CroFab® or DigiFab® please call 1-877-377-3784.This is a 24 hour hotline staffed with medical personnel who can address all of your questions and concerns.

According to the Code of Federal Regulations, an adverse drug experience is defined as any reaction that may be associated with the use of the drug: Any adverse event associated with the use of a drug in humans, whether or not considered drug related, including the following: An adverse event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action. Who should be contacted in the event of an ADE? To report an ADE, please contact ALTANA Inc within 24 hours: Complaint Specialist, Nycomed US Inc. Telephone: (631) 454-7677.

Please contact Customer Service in the contact us section of the website for information about becoming a distributor of Fougera products.

Providing we do not already have an exclusive distributor in the territory, we must review the registration requirements of the importing country as well as determine the sales potential in the region.

Various Fougera products can be found through our distributors in the following regions: Guyana, Peru, Argentina, Honduras, Costa Rica, Dominican Republic, Jamaica, Trinidad, Tabago, Barbados, Guam, Aruba, Mexico, Canada, Cyprus, Panama, Netherlands, United Kingdom, Israel, Hong Kong, Ireland, Saudi Arabia, Japan, Taiwan, Korea, Italy, Guatemala, New Zealand, El Salvador, Chile, Australia, Kuwait and the Philippines to name a few.

You can contact Maureen Ruddy at 631-454-7677 ext. 3041 or maureen.ruddy@nycomedus.com

CroFab® - Crotalidae Polyvalent Immune Fab (Ovine) is a blood/serum-derived product. CroFab® is not a recombinant product, it is a polyclonal antibody fragment product derived from the whole blood of sheep. All antivenoms are produced in this manner as it is nearly impossible to make a recombinant antivenom since venom is comprised of hundreds of antigens. If your religion prevents you from being treated with anything derived from the blood of animals, you would not be able to receive any antivenoms.

The need to have dual sourcing for CroFab® - Crotalidae Polyvalent Immune Fab (Ovine) is to minimize the risks to market supply. The goal for CBL is to aid in the production of CroFab®, which will allow for a continuous supply. An additional advantage will be a shorter product supply chain and streamlined logistical activities.

Due to the differences in the actual lyophilizer hardware, some modifications were needed in the freeze-drying process. These modifications are considered minor, and the products produced from either process are equivalent, as supported by the data generated during the CBL qualification program and the ongoing stability trials.

The Mayne vial is slightly larger and has a slanted shoulder region while the CBL vial is slightly smaller and has a flat shoulder region. The motivation for changing the vial type is security of supply. The Mayne vial is very difficult to purchase in sufficient volumes and the manufacturer of the vial is a small specialist supplier. The manufacturer of the CBL vial is a major manufacturer and supplies vials of this type for a multitude of products. It is a relatively generic vial type, which helps with securing supplies and controlling costs. The outer carton for the product coming from CBL will be slightly smaller than the outer carton from Mayne, due to the fact that the vials are also slightly smaller and thus require smaller packaging. There is no difference in the color or appearance of the product within the vial. (Click to compare CBL and Mayne packaging)

Due to the fact that the CBL product vial is slightly smaller in diameter, a slight increase in the height of the cake may be observed. The cake consistency and appearance is indistinguishable between the Mayne and CBL product.

The reconstitution and treatment protocols are the same, as the number of vials per dose and relative total potency per vial is identical between the Mayne and CBL CroFab™ - Crotalidae Polyvalent Immune Fab (Ovine) products.